Vision loss in patients with giant cell arteritis treated with tocilizumab
OBJECTIVES: Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) is able to prevent vision loss is unknown. The aim was to analyze the occurrence of vision loss in a large GCA cohort treated with TCZ.
METHODS: In this observational monocentric study, GCA patients treated with TCZ between the years 2010 and 2018 were studied. Demographic, clinical, and laboratory data were analyzed.
RESULTS: A total of 186 patients were included (62% female); 109 (59%) fulfilled the American College of Rheumatology (ACR) criteria, in 123 (66%) patients, large vessel vasculitis was diagnosed by magnetic resonance-angiography (MRA). Cumulative duration of TCZ treatment was 224 years, median treatment duration was 11.1 (IQR 5.6-17.9) months. Glucocorticoids (GC) were tapered over a median of 5.8 (IQR 3.0-8.5) months. At baseline, visual symptoms were present in 70 (38%) and vision loss in 21 (11%) patients. Patients with vision loss at baseline were older (p = 0.032), had a lower C-reactive protein (p = 0.002), and showed a negative association with MRA of the aorta (p = 0.006). Two patients (1.1%) developed vision loss, both at the initiation of TCZ treatment.
CONCLUSION: Our data show a very low incidence of vision loss in TCZ-treated patient. The two cases of AION occurred at the initiation of therapy, they support the hypothesis that advanced, and established structural changes of arteries are key factors for this accident. Whether a shorter duration of concomitant GC treatment is risky regarding vision loss needs to be studied.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Arthritis research & therapy - 23(2021), 1 vom: 22. März, Seite 92 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Amsler, Jennifer [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anterior ischemic optic neuropathy (AION) |
|---|
| Anmerkungen: |
Date Completed 21.06.2021 Date Revised 21.06.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13075-021-02480-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323090613 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323090613 | ||
| 003 | DE-627 | ||
| 005 | 20231225183425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13075-021-02480-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM323090613 | ||
| 035 | |a (NLM)33752737 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Amsler, Jennifer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vision loss in patients with giant cell arteritis treated with tocilizumab |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2021 | ||
| 500 | |a Date Revised 21.06.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) is able to prevent vision loss is unknown. The aim was to analyze the occurrence of vision loss in a large GCA cohort treated with TCZ | ||
| 520 | |a METHODS: In this observational monocentric study, GCA patients treated with TCZ between the years 2010 and 2018 were studied. Demographic, clinical, and laboratory data were analyzed | ||
| 520 | |a RESULTS: A total of 186 patients were included (62% female); 109 (59%) fulfilled the American College of Rheumatology (ACR) criteria, in 123 (66%) patients, large vessel vasculitis was diagnosed by magnetic resonance-angiography (MRA). Cumulative duration of TCZ treatment was 224 years, median treatment duration was 11.1 (IQR 5.6-17.9) months. Glucocorticoids (GC) were tapered over a median of 5.8 (IQR 3.0-8.5) months. At baseline, visual symptoms were present in 70 (38%) and vision loss in 21 (11%) patients. Patients with vision loss at baseline were older (p = 0.032), had a lower C-reactive protein (p = 0.002), and showed a negative association with MRA of the aorta (p = 0.006). Two patients (1.1%) developed vision loss, both at the initiation of TCZ treatment | ||
| 520 | |a CONCLUSION: Our data show a very low incidence of vision loss in TCZ-treated patient. The two cases of AION occurred at the initiation of therapy, they support the hypothesis that advanced, and established structural changes of arteries are key factors for this accident. Whether a shorter duration of concomitant GC treatment is risky regarding vision loss needs to be studied | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Anterior ischemic optic neuropathy (AION) | |
| 650 | 4 | |a Giant cell arteritis | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 4 | |a Vision loss | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Kysela, Iveta |e verfasserin |4 aut | |
| 700 | 1 | |a Tappeiner, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Seitz, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Christ, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Scholz, Godehard |e verfasserin |4 aut | |
| 700 | 1 | |a Stalder, Odile |e verfasserin |4 aut | |
| 700 | 1 | |a Kollert, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Reichenbach, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Villiger, Peter M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis research & therapy |d 2003 |g 23(2021), 1 vom: 22. März, Seite 92 |w (DE-627)NLM124870457 |x 1478-6362 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:1 |g day:22 |g month:03 |g pages:92 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13075-021-02480-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 1 |b 22 |c 03 |h 92 | ||